双歧杆菌四联活菌片治疗腹泻型肠易激综合征患者的疗效及对血清脑肠肽水平的影响  

Efficacy of Bifidobacterium Tetravaccine tablets on serum ghrelin levels of patients with diarrhea irritable bowel syndrome

作　　者：傅丽霞[1] 

机构地区：[1]丽水市中心医院消化内科,浙江丽水323000

出　　处：《中国微生态学杂志》2017年第2期179-181,共3页Chinese Journal of Microecology

摘　　要：目的探讨双歧杆菌四联活菌片治疗腹泻型肠易激综合征(IBS-D)患者的疗效及对血清脑肠肽水平的影响。方法选择82例治疗中的IBS-D患者,随机分为观察组(n=41例)和对照组(n=41例)。两组患者均予以饮食调整、消化道解痉药和止泻药等基础治疗。观察组患者口服双歧杆菌四联活菌片1.5g/次,3次/d,连用8周。对照组患者除不使用双歧杆菌四联活菌片外其余处理同观察组。观察并记录两组患者治疗后疗效及不良反应,并比较治疗前后血管活性肠肽(VIP)和P物质(SP)水平的变化。结果观察组与对照组治疗期间分别失访2例和4例,两组失访率比较差异无统计学意义(χ~2=0.18,P>0.05)。治疗8周后,观察组临床总有效率为92.31%,较对照组的75.68%更佳(χ~2=3.95,P<0.05);同时两组血清VIP水平较治疗前明显上升,SP水平较治疗前明显下降(P<0.05或P<0.01),且观察组上升或下降幅度较对照组更明显(P<0.05)。对照组和观察组治疗中分别出现不良反应3例和5例,症状较轻,两组比较差异无统计学意义(χ~2=0.09,P>0.05)。结论双歧杆菌四联活菌片在IBS-D治疗中的应用效果较好,能较快并能持久缓解其症状,且安全性较好,其作用机制与其升高血清VIP水平,降低血清SP水平,纠正血清脑肠肽水平异常密切相关。Objective To explore the efficacy of Bifidobacterium Tetravaccine tablets on serum ghrelin levels of patients with with Diarrhea Irritable Bowel Syndrome（IBS-D）.Methods 82 outpatients with IBS-D were selected and randomly divided into observation group（n=41）or control group（n=41）,and given basic treatment with diet adjustment,gastrointestinal antispasmodic drug and antidiarrheal agent etc.The patients in observation group were additionally given Bifidobacterium Tetravaccine tablets 1.5g t.i.d.orally for 8weeks.The changes of the levels of serum vasoactive intestinal peptide（VIP）and substance（SP）before and after treatment,as well as the clinical efficacy and drug adverse reactions（DARs）after treatment were observed and compared between groups.Results 2and 4cases of loss to follow-up occurred in observation group and control group respectively,with no statistical difference（χ2=0.18,P〉0.05）.The total clinical efficiency in observation group was much higher than that in control group（92.31% vs.75.68%）（χ2=3.95,P〈0.05）.The serum VIP levels increased,while the serum SP levels declined in both groups after treatment（P〈0.05 or P〈0.01）,with the increasing or declining rate in observation group much higher than those in control group（P〈0.05）.3and 5cases of adverse reactions appeared in control group and observation group respectively during the treatment with mild symptoms;no statistical difference was seen between the two groups（χ2=0.09,P〈0.05）.Conclusion Bifidobacterium Tetravaccine Tablet has favorable clinical efficacy and high safety for IBS-D,which can promptly and persistently relieve the clinical symptoms of patients.The mechanisms of action may be closely related to its effects of increasing VIP level while reducing serum SP level and adjusting abnormal serum ghrelin level.

关 键 词：肠易激综合征 腹泻型 双歧杆菌四联活菌片 脑肠肽 

分 类 号：R378[医药卫生—病原生物学]